Patents by Inventor Deborah Goldberg

Deborah Goldberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-RSV MONOCLONAL ANTIBODY FORMULATION
    Publication number: 20230399383
    Abstract: The present invention provides a formulation comprising: (i) an anti-RSV monoclonal antibody; and (ii) an ionic excipient; wherein the monoclonal antibody is present at a concentration of about 50 mg/ml or greater and the ionic excipient is present at a concentration of between 50 and 150 mM and the formulation has a pH of about 5.5 to about 7.5.
    Type: Application
    Filed: April 28, 2023
    Publication date: December 14, 2023
    Inventors: Brian LOBO, Deborah GOLDBERG
  • Anti-RSV monoclonal antibody formulation
    Patent number: 11667698
    Abstract: The present invention provides a formulation comprising: (i) an anti-RSV monoclonal antibody; and (ii) an ionic excipient; wherein the monoclonal antibody is present at a concentration of about 50 mg/ml or greater and the ionic excipient is present at a concentration of between 50 and 150 mM and the formulation has a pH of about 5.5 to about 7.5.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: June 6, 2023
    Assignee: MedImmune Limited
    Inventors: Brian Lobo, Deborah Goldberg
  • Anti-RSV monoclonal antibody formulation
    Patent number: 11286294
    Abstract: The present invention provides a formulation comprising: (i) an anti-RSV monoclonal antibody; and (ii) an ionic excipient; wherein the monoclonal antibody is present at a concentration of about 50 mg/ml or greater and the ionic excipient is present at a concentration of between 50 and 150 mM and the formulation has a pH of about 5.5 to about 7.5.
    Type: Grant
    Filed: June 18, 2021
    Date of Patent: March 29, 2022
    Assignee: MEDIMMUNE LIMITED
    Inventors: Brian Lobo, Deborah Goldberg
  • ANTI-RSV MONOCLONAL ANTIBODY FORMULATION
    Publication number: 20210317191
    Abstract: The present invention provides a formulation comprising: (i) an anti-RSV monoclonal antibody; and (ii) an ionic excipient; wherein the monoclonal antibody is present at a concentration of about 50 mg/ml or greater and the ionic excipient is present at a concentration of between 50 and 150 mM and the formulation has a pH of about 5.5 to about 7.5.
    Type: Application
    Filed: June 18, 2021
    Publication date: October 14, 2021
    Inventors: Brian Lobo, Deborah Goldberg
  • ANTI-RSV MONOCLONAL ANTIBODY FORMULATION
    Publication number: 20200339667
    Abstract: The present invention provides a formulation comprising: (i) an anti-RSV monoclonal antibody; and (ii) an ionic excipient; wherein the monoclonal antibody is present at a concentration of about 50 mg/ml or greater and the ionic excipient is present at a concentration of between 50 and 150 mM and the formulation has a pH of about 5.5 to about 7.5.
    Type: Application
    Filed: July 13, 2020
    Publication date: October 29, 2020
    Inventors: Brian Lobo, Deborah Goldberg
  • Anti-RSV monoclonal antibody formulation
    Patent number: 10774133
    Abstract: The present invention provides a formulation comprising: (i) an anti-RSV monoclonal antibody; and (ii) an ionic excipient; wherein the monoclonal antibody is present at a concentration of about 50 mg/ml or greater and the ionic excipient is present at a concentration of between 50 and 150 mM and the formulation has a pH of about 5.5 to about 7.5.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: September 15, 2020
    Assignee: MedImmune Limited
    Inventors: Brian Lobo, Deborah Goldberg
  • ANTI-RSV MONOCLONAL ANTIBODY FORMULATION
    Publication number: 20180251526
    Abstract: The present invention provides a formulation comprising: (i) an anti-RSV monoclonal antibody; and (ii) an ionic excipient; wherein the monoclonal antibody is present at a concentration of about 50 mg/ml or greater and the ionic excipient is present at a concentration of between 50 and 150 mM and the formulation has a pH of about 5.5 to about 7.5.
    Type: Application
    Filed: February 28, 2018
    Publication date: September 6, 2018
    Inventors: Brian Lobo, Deborah Goldberg